PetMedicus Laboratories Receives MUMS Designation for Ondansetron (VML-028) in Cisplatin-Induced Emesis.
View post, or download PDF.

EVALUATION OF THE ORAL ANTIMITOTIC, ABT-751, ALONE AND IN COMBINATION AN ANTIANGIOGENIC PEPTIDE OF THROMBOSPONDIN-1, ABT-510, IN DOGS WITH LYMPHOMA.
View post, or download PDF.

A randomized placebo-controlled clinical trial of the anti-angiogenic thromobspondin-mimetic peptide ABT-526 plus Lomustine chemotherapy versus Lomustine chemotherapy alone in pet dogs with relapsed non-Hodgkin’s lymphoma.
View post, or download PDF.

A Randomized Placebo-Controlled Clinical Trial of ABT-526 Antiangiogenic Therapy Plus Lomustine Chemotherapy Versus Lomustine Chemotherapy Alone in Dogs With Relapsed Lymphoma.
View post, or download PDF.

Antiangiogenic Thrombospondin-I peptides result in regression of naturally occurring cancers in pet dogs.
View post, or download PDF. Also, download a large, full-color PDF poster of this publication.

Tumor inhibition by antiangiogenic TSP-I mimetic peptides.
View post.

A new option for the treatment of canine lymphoma.
View post, or download PDF.

Targeting the blood supply of cancer.
View post, or download PDF.

Ongoing evaluation of single agent thalidomide in dogs with measurable cancer.
View post, or download PDF.